Andrew Green, MD
Gynecologic Oncology · Shreveport, LANPI 1396943973
Payments from drug & device makers
Across 339 payments — averaging $2413.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$370K
- Merck$314K
- Novocure Inc.$80K
- Tesaro, Inc.$23K
- GSK$21K
- Intuitive Surgical$6K
- plus $3K from 24 others
Across 2 payments — averaging $230.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$461
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 22 | $370,345 |
| Merck | 83 | $314,291 |
| Novocure Inc. | 10 | $80,386 |
| Tesaro, Inc. | 57 | $23,405 |
| GSK | 37 | $21,142 |
| Intuitive Surgical | 45 | $5,753 |
| Hologic Sales And Service, LLC | 9 | $624 |
| Myriad Genetic Laboratories, Inc. | 10 | $606 |
| AstraZeneca | 15 | $291 |
| Medtronic | 3 | $245 |
| Clovis Oncology, Inc. | 9 | $154 |
| Eisai Inc. | 7 | $145 |
| Daiichi Sankyo Inc. | 7 | $123 |
| Aroa Biosurgery Incorporated | 2 | $114 |
| Seagen Inc. | 3 | $75 |
| Pfizer | 2 | $46 |
| Genentech USA, Inc. | 3 | $46 |
| KCI USA, Inc. | 2 | $40 |
| Heron Therapeutics, Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $29 |
| Novartis | 1 | $24 |
| Immunogen, Inc. | 1 | $22 |
| AbbVie | 1 | $22 |
| Olympus America Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Biom'up France SAS | 1 | $20 |
| Fortovia Therapeutics, Inc. | 1 | $20 |
| Morphosys, US Inc. | 1 | $18 |
| Exeltis, USA Inc. | 1 | $18 |
| Davol Inc. | 1 | $12 |
How this compares
Too few gynecologic oncology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Shreveport
- Destin BlackShreveport$4.7M
- Ricky OwersShreveport$19
- Patricia BralyCovington$6M
- Katrina WadeNew Orleans$1.1M
- Amma AgyemangMetairie$23K
- Jacob EstesNew Orleans$16K
- Milton FortBaton Rouge$9K
- Jessica ShankNew Orleans$4K
- David BarringtonNew Orleans$2K
- Diogo TorresNew Orleans$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.